Dr Carles Galdeano is currently an Associate Professor at University of Barcelona. He obtained his PhD in medicinal chemistry at University of Barcelona with two visiting stays at Virginia Tech (USA) and CNRS (France). After that, he spent three years as a post-doc in the Alessio Ciulli’s lab (first at University of Cambridge and later at University of Dundee) where together they developed the first potent VHL ligands described. His postdoctoral discoveries represented a breakthrough in the PROTACs field. In 2015, he returned to the University of Barcelona to work in collaboration with Prof Barril with a Beatriu de Pinos Fellowship until 2019, when he started his independent research group. In 2021, he founded Oniria Therapeutics.

Relevant positions

• Co-Founder and Scientific Advisor in drug discovery at Oniria Therapeutics
• Secretary at the Biomedicine Institute at the University of Barcelona (IBUB)
• Group leader of one working group of the Proteocure
• Director of EDDU